Essure* present controversies and 5 years learned lessons: a retrospective study with short and long term follow-up. by Câmara, Sara et al.
Gynecological SurgeryCâmara et al. Gynecological Surgery  (2017) 14:20 
DOI 10.1186/s10397-017-1023-3ORIGINAL ARTICLE Open AccessEssure® present controversies and 5 years’
learned lessons: a retrospective study with
short- and long-term follow-up
Sara Câmara* , Filipa de Castro Coelho, Cláudia Freitas and Lilia RemessoAbstract
Background: The risk-benefit of contraception with Essure® is being readdressed due to an increase of reports of
adverse effects with this device. Our aim was to proceed to an internal quality evaluation and to identify opportunities
for protocol improvement.
We proceeded to a one-center, retrospective consecutive case series of women admitted for Essure® placement, from
1 January 2012 until 31 December 2016 (5 years).
Results: In a total of 274 women, technical difficulties were mainly unilateral, with no acute or short-term severe
complications. The procedure was brief (median 3.2 min, IQR 2.5–5.2) and moderately painful (median of 4 in a 0–10
scale; IQR 3–5). At 3 months, the failure rate was 2%, with no pregnancies. Second surgery indication (< 1%) resumed
to a case of nickel hypersensitivity. At 1 year, pregnancy rate was 1%. Ninety-eight percent of the patients would
recommend the method.
Conclusions: We identified high patient satisfaction and low failure rates, both at short and long term. Investigation
about whether some women still have patent tubes at the 3-month follow-up could lead to protocol improvement. It is
important that clinicians look for second causes for adverse effects related to Essure® and avoid the erroneous indication
for implant removal. Long follow-up allowed for both internal quality evaluation and clarification of misconception; it
could possibly also have contributed to patient satisfaction.
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Office hysteroscopic sterilization is more cost-effective than
laparoscopic sterilization and is a better option in high-
operative-risk women [1]. Its success depends on careful
patient selection, surgeon’s experience, reliable compliance
of back-up contraception, and observance of the 3-month
follow-up [2]. Recently, there has been an imperative urge
to survey Essure® risk-benefit profile during its life cycle,
due to an intensification of adverse effect report [2, 3].
While being a highly satisfactory permanent contra-
ception method, pelvic pain (related or not to menses)
and irregular bleeding or heavy menstruation are among
the most frequent late complications related to the
procedure [2]. However, these symptoms are not always* Correspondence: sara.cam.camara@gmail.com
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the Creative Commons license, and indicate ifrelated to the micro-inserts itself but to other underlying
gynecologic conditions (endometriosis, adenomyosis, or
others), which could erroneously indicate the implant
surgical removal [2, 4].
Several studies have been reported which describe long-
term follow-ups (from 1 to 5 years) of patients submitted
to sterilization with Essure® [5–7]. In this study, the
authors have proceeded to a retrospective consecutive
case series analysis of one-center (two hysteroscopists),
5 years’ experience with Essure®. The authors’ aim was first
to evaluate internal quality (procedure-associated surgical
difficulties; patient acute complications; failure and
pregnancy rates; adverse effects; and satisfaction at long
follow-up) and second, to identify opportunities for
protocol improvement.is distributed under the terms of the Creative Commons Attribution 4.0
rg/licenses/by/4.0/), which permits unrestricted use, distribution, and
e appropriate credit to the original author(s) and the source, provide a link to
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A retrospective case series analysis of women admitted to
hysteroscopy with intention to treat for Essure® placement,
at our center, from 1 January 2012 until 31 December
2016, was done.
Patient selection always included a previous standardized
initial appreciation and information on this permanent
contraception method (Table 1). All women received
contraceptive counseling and were clinically evaluated by
one of the two hysteroscopists, who would realize the
procedure. Premedication with paracetamol or with
non-steroidal anti-inflammatory was used at patient discre-
tion, and this information could not be retrospectively
confirmed. At all times, the placement of the micro-inserts
was accomplished by vaginoscopy, without anesthesia or
cervical dilatation. Women who were not using contracep-
tion at this moment or who were using barrier methods
would be advised to start a hormonal contraceptive pill for
back-up contraception, except if contraindicated.
Collected variables were:
– demographic characteristics (age, gravidity, parity,
contraceptive method in use);
– procedure description (surgeon’s perceived difficulty;
duration of the procedure from the hysteroscope
entrance until its exit from the uterine cervix
external ostium; patient reported pain immediately
after the procedure, in a numeric scale of 1–10);
– follow-up at 3 months (consisting of an appointment
with the hysteroscopist of reference to monitor early
complications; confirm correct localization of the
micro-inserts either by X-ray, gynecological ultrasound,
hysterosalpingography, or hysterosonography; and
inform the patient if the back-up contraception should
be prolonged or abandoned);Table 1 Previous counseling included items
▪ Full gynecological evaluation (clinical history, gynecological
observation, transvaginal ultrasound, and cervical and breast
cancer screening if indicated)
▪ Confirming the motivation to permanent contraception
▪ Evaluation of nickel or metal allergy
▪ Full information on the procedure (anatomical and technical details)
▪ Full information on possible
complications and restrictions
Early: infection, acute pain,
perforation/migration/expulsion
Late: chronic pain or irregular/heavy
bleeding
Restrictions:
✓ Magnetic resonance—safe if
using a 1.5 T magnet; artifact
possibility
✓ Electrosurgical procedures—
should be avoided if near the
micro-inserts– and follow-up after the first completed year (women
were contacted by phone by the same medically
trained operator and were asked to classify their
satisfaction with the method as “very unsatisfied,”
“unsatisfied,” “satisfied,” or “completely satisfied” to
state reasons in case they were not completely
satisfied and if they would likely recommend this
method).
Finally, failure (defined by incorrect micro-implant
localization or tubal permeability) rates and pregnancy
rates at 3 months and 1 year were calculated, and second
surgery requirement and indication were explored.
Results
Essure® delivery
During 5 years, 274 women were admitted to hysteros-
copy with intention to treat for Essure® delivery (Table 2).
This was not achieved bilaterally in 7.3% of the patients
mainly because of obstruction to the delivery catheter
progression but also because of non-identified ostium or
ostia (Table 3). The minority of patients with non-
identified ostium or ostia were using continuous hormonal
contraception (either a combined estroprogestative or a
progestative-only pill). Device (manufacturer)-related diffi-
culties were not identified. Women who could not be
successfully sterilized with Essure® underwent either
laparoscopic tubal ligation or salpingectomy (according to
the woman’s informed choice). There were no severe acute
complications. The only acute complication was one case
of vagal reaction, immediately after successful implant
delivery (with complete satisfaction at long follow-up).
Early (3 months) follow-up (n = 254)
For the 3-month follow-up, we considered the 254
women with successful delivered micro-inserts. No loss
of follow-up or pregnancy was registered. In 2% (n = 4),
the confirmatory exams revealed that the procedure wasTable 2 Demographic characteristics of patients submitted to
hysteroscopy for Essure® delivery
Age (years) mean = 38
(SD = 4; range 27–46)
Gravidity median = mode = 2
(IQR 2–3; range 0–7)
Parity median = mode = 2
(IQR 2–3; range 0–6)
Previous contraceptive method ▪ SARC users: 65% (n = 178),
of which 96% (n = 171) were
using a contraceptive pill
▪ LARC users 15% (n = 42)
▪ Others (barrier or natural
method of contraception)
20% (n = 54)
SARC short-acting reversible contraception, LARC long-acting
reversible contraception
Table 3 Procedure description
Surgical difficulties ▪ Surgeon’s perceived difficulty in
inserts delivery 11% (n = 31), of
which 65% (n = 20) unilateral
▪ Successful placement not achieved
in 7.3% (n = 20):
✓ tube obstruction because of
spasm/stenosis (n = 16)
✓ non-identified ostium/ostia (n = 4)
Hysteroscopy duration
(minutes)
Δt median 3.2 (IQR 2.5–5.2; range 1–15)
Patient reported pain
(0–10 scale)
median score = 4 (IQR 3–5; range 0–8);
mode = 3
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leakage in the post-salpingectomy side, with confirmed
contralateral obstruction; and one case of insert unilat-
eral expulsion, brought in hand by the patient and
confirmed by imaging). This last patient underwent
subsequent placement of a new micro-insert which she
again noticed to deliver per the vagina some days after-
wards (with correct number of coils trailing in uterine
cavity, namely three, bilaterally and without perceived
surgical difficulty during its placement).
During this first trimester, there were no cases of fever,
documented infection, or pelvic pain requiring further care.
One allergic reaction to nickel manifested shortly after
the 3-month follow-up with a generalized dyshidrotic
eczema, and this was confirmed by immunoallergology
patch test. This woman had no history of allergy to metals,
and the situation resolved completely after hysterectomy
(which was the decision taken together with patient,
considering the surgical risks of a more conservator
approach, including that of incomplete device removal).Late (≥ 1 year) follow-up, complications, and satisfaction
(n = 249)
Considering the patients with a 3-month follow-up
which confirmed correct Essure® placement, a total of
249 patients had the implants for more than 1 year
before. Not all these patients could be contacted by tele-
phone at several attempts. At the end, 72% of them
(n = 179) answered to the satisfaction survey; 88%
(n = 158) were completely satisfied and 9% (n = 17) were
very satisfied but reported abnormal menstrual bleeding
and/or pelvic pain (related or not to menstruation). Two
percent (n = 4) were unsatisfied or very unsatisfied and
were the only who would not recommend this method
of contraception (two of these women had the same
symptoms than the other patients but more severe,
requiring the reintroduction of hormonal therapy; the
other two women had correct micro-insert placement
documented by either X-ray and ultrasound or by hys-
terosalpingography but reported a pregnancy diagnosedat their private medical assistance). Assuming these two
cases of pregnancy, the pregnancy rate at 1 year was 1%.
In this satisfaction survey, two women pointed out
that they had been denied magnetic resonance. This
question was readdressed and clarified during the satis-
faction survey. Some women revealed misconceptions
about the procedure (relating it to the posterior appear-
ance of an adnexal mass or to abnormal cervical smear),
which was elucidated at that moment.
Discussion
Although there are presently many controversies about
Essure®, evidence about long-term follow-up of patients
submitted to this type of definitive contraception is
scarce. The importance to proceed to an extended
survey of patients’ satisfaction has been unanimously
strengthened by previous studies [5–9]. In what con-
cerns the demographic findings in our population, they
are similar to what has been described by others [5–9].
Surgical difficulty and unsuccessful procedure
In our experience, the surgeon perceived the procedure as
difficult in 11% of the cases (mainly unilateral difficulty),
with an unsuccessful micro-insert delivery (either with or
without attempt), comparable to the results found in the lit-
erature (7.3 versus 1.5% [9], 2.8% [7], 8% [6], 12% [10]). Sys-
tematic use of a non-steroidal anti-inflammatory or a
spasmolytic before the procedure (except if contraindi-
cated) could possibly contribute to diminish tubal spasm
and subsequent obstruction, but this is yet to be probed.
Although we had no event of perforation or abdominal
migration, these events could be related to tubal cannula-
tion attempts and, therefore, also benefit from tubal spasm
prevention. In what concerns continuous hormonal contra-
ception, it is thought to improve visibility and therefore
facilitate the implant delivery. Theoretically, continuous
progestins, instead of combined hormonal contraception,
may be more favorable due to a higher atrophic effect of
the endometrium, but this is not evidence-based. In our
sample, however, all women with non-identified ostium/
ostia were using continuous hormonal contraception.
Patient acute complications
Besides acute pain and one self-limited vagal reaction,
we had no other incidents like perforation, syncope, or
infection. In the literature, there is no evidence about
acute complication incidence, but our findings and of
others support that this procedure is moderately painful
even if brief [5–8]. An incidence of 4.2% of pain chroni-
fication (lasting more than 3 months after the proced-
ure) has been estimated [10]. Because our study is
retrospective, we could not identify our incidence of
chronic pain.
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A good adherence to the 3-month confirmatory tests and
back-up birth control after hysteroscopic sterilization is
important to avoid unintended pregnancies. Remarkably,
we had no loss to follow-up or pregnancy events at
3 months, with a correct placement confirmed in 99% of
the tests which is analogous to previous publications
(99.5% [7] and 99.6% [9]; even if in these series a lower
first control compliance rate is reported 90.8 and 96.8%,
respectively). Our 3-month follow-up detected failures
were due to contrast leakage or micro-insert expulsion. In
the second case, we would now opt for another type of
sterilization instead of a second attempt. In view of the
fact that the implant expulsed had been delivered with no
difficulty, that a correct number of coils trailed in the
cavity, and the facility at which it was asymptomatically
expulsed, we can imagine that there can be a sort of tubal
incompetency.
At 1-year follow-up, we had two pregnancies reported
(corresponding to a failure rate of 1%), after documented
correct micro-inserts localization. Both, incorrect inter-
pretation of those tests or correct interpretation of
localization tests but without obstruction confirmation,
are plausible explanations. However, it may also be
hypothesized that some women may produce less or
slower reaction to the implant, accounting for cases of
migration or expulsion, or even for cases of pregnancy
after the 3-month correct follow-up. In agreement with
this hypothesis, higher than expected tubal patency at
intervals less than 1 year [11] and cases of pregnancy after
the 3-month ideal follow-up have been published [2, 7].
Failure rates of all types of sterilization failures are esti-
mated in 0.9% [12] but there is uncertainty about specific
failure rates for Essure® due to either short follow-up stud-
ies, discrepancy between study results, or lack of informa-
tion on follow-up or on accomplished protocol [13, 14].
Adverse effects and satisfaction at long follow-up
Complication rate for laparoscopic sterilization has been
estimated in 1.6% [15]. In our study, we had no case of
infection, perforation, embolus, or death. Considering
the case of nickel hypersensitivity, our post-procedure
second surgery was 0.4%. We consider that the suspicion
of nickel allergy should contraindicate the procedure
even if since 2011 this is no longer contraindicated by
the Food and Drug Administration and if some authors
would recommend further evaluation but nevertheless
consider the procedure [7]. In the manufacturer’s official
site, it can be read that no test can reliably predict this
adverse effect [16].
Like in our study, studies evaluating women satisfac-
tion have constantly found high levels of early and late
satisfaction with levels of moderate or lower pain [6–8].
The most frequent reported secondary adverse effectsare pelvic pain (with or without dysmenorrhea) and
increased menses bleeding or irregularity [2]. Unfortu-
nately, we could not assess “de novo” pain cases because
most of these women were previously under hormonal
contraception, which could have masked previous symp-
toms. Resuming hormonal therapy ameliorated the symp-
toms, avoiding the need for second surgery for implant
removal (guaranteeing a more effective contraception).
Others have enlightened the importance to clearly evalu-
ate the complaints that patients relate to Essure®, at the
risk of removing the implants without improvement [2, 4].
With reported second surgery rates of 0.4% [7] to 4.3%
[4], according to a recent retrospective cohort study, more
than half of surgeries post-Essure® placement were related
to pain complaints and the majority of them related to
subjacent gynecological conditions [4]. We believe that
this finding is of great relevance for clinicians who
evaluate women with Essure®.Final considerations
The most important weakness of our study is its retro-
spective nature. With our findings, we now look forward
to proceed in our investigation in a prospective way and
to a longer interval of follow-up.
Finally, we believe that the possibility to inform women
about misconceptions of long-term effects of the method
contributes to a higher patient satisfaction, though this has
not been previously studied. Further investigation is needed
to identify which benefits can be obtained by premedication
and if a different first follow-up control could have higher
sensitivity in the detection of the method failure.Conclusions
From 5 years of experience with Essure®, we identified
very high rates of satisfaction with this extremely
effective and accessible method, associated to moderate
pain in a fast procedure, with a low need for second
surgery. The unsatisfaction related to the method is
usually due to misconceptions about it, which is why we
attribute great relevance to prior candidate selection and
specific counseling. Long follow-up allows for both
further identification of method failure and for a second
chance for misconception clarification. It can probably
also contribute to a higher patient satisfaction.
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